Routine ultrasound progressed femoral get admission to; did no longer decrease bleeding, vascular headaches

source:The Bump

TCT Scientific Symposium; Sept. 16-19, 2022; Boston (hybrid meeting).

source:The Bump

Jolly SS, et al. Late-Breaking Clinical Science in Vascular Disease and Hypertension: Session III, in Collaboration With the Journal of the American Medical Association.

source:The Bump

Jolly reports receiving grant/research support from Boston Scientific and consultant fees/honoraria from Medtronic and Penumbra.

source:The Bump

The results of the UNIVERSAL trial were presented at TCT 2022 and simultaneously published in JAMA Cardiology.

source:The Bump

Although numerically fewer in the ultrasound-guided femoral access group, occurrences of the primary outcome

source:The Bump

and any of its individual components did not significantly differ between ultrasound-guided and non-ultrasound guided femoral access:

 BARC 2, 3 or 5 bleeding or major vascular complications (ultrasound, 12.9%; controls, 16.1%; OR = 0.77; 95% CI, 0.49-1.2; P = .25);

– BARC 2, 3 or 5 bleeding (P = .78); – major vascular complications (P = .18); and – BARC 2 bleeding (P = .78).

The odds of an adverse fluoroscopy event following femoral access were lower in the ultrasound-guided group compared with the non-ultrasound-guided group when a closure device was used (OR = 0.44; 95% CI, 0.23-0.82; P for interaction with no closure device = .004).

Additionally, Jolly and colleagues completed a meta-analysis of nine studies — consisting of UNIVERSAL — that defined bleeding activities and vascular headaches following coronary techniques requiring femoral get right of entry to